Efficacy and Safety of Linagliptin/Metformin Fixed-Dose Combination (FDC) as Initial Therapy in Asian Patients with Type 2 Diabetes (T2D) and Severe Hyperglycemia

被引：0
|
作者：
Mu, Yiming
Pan, Changyu
Fan, Bei
Hehnke, Uwe
Gong, Yan
机构：
来源：
DIABETES | 2015年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1218-P
引用
收藏
页码：A315 / A315
页数：1
相关论文
共 50 条
  • [31] Fixed-dose combinations in type 2 diabetes - role of the canagliflozin metformin combination
    Fleming, Joshua W.
    Fleming, Laurie W.
    Davis, Courtney S.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2015, 8 : 287 - 294
  • [32] Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview
    Jaime A. Davidson
    Lance Sloan
    Advances in Therapy, 2017, 34 : 41 - 59
  • [33] Linagliptin/metformin HCl (fixed combination therapy) for the treatment of Type 2 diabetes mellitus
    Bhargava, Amit
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2015, 10 (04) : 353 - 363
  • [34] Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naive patients with type 2 diabetes
    Perez-Monteverde, A.
    Seck, T.
    Xu, L.
    Lee, M. A.
    Sisk, C. M.
    Williams-Herman, D. E.
    Engel, S. S.
    Kaufman, K. D.
    Goldstein, B. J.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (09) : 930 - 938
  • [35] Initial Therapy with the Fixed-Dose Combination of Sitagliptin and Metformin Results in Greater Improvement in Glycemic Control Compared with Pioglitazone in Patients with Type 2 Diabetes
    Katz, Leonid
    Xu, Lei
    Hussain, Shehla
    Golm, Gregory T.
    O'Neill, Edward A.
    Kaufman, Keith D.
    Goldstein, Barry J.
    Williams-Herman, Debora E.
    DIABETES, 2010, 59 : A148 - A149
  • [36] Safety and Tolerability of Linagliptin and Metformin in Combination for Patients with Type 2 Diabetes Mellitus (T2DM)
    Ross, Stuart A.
    Haak, Thomas
    Patel, Sanjay
    Thiemann, Sandra
    Schumacher, Helmut
    Meinicke, Thomas
    DIABETES, 2014, 63 : A277 - A277
  • [37] Gene Expression and Metformin Efficacy in Type 2 Diabetes (T2D)
    Prudente, Sabrina
    Masotti, Andrea
    Copetti, Massimiliano
    Caporarello, Nunzia
    Proto, Vittoria
    Da Sacco, Letizia
    Morini, Eleonora
    Mercuri, Luana
    Bailetti, Diego
    Palena, Antonio
    Baratta, Roberto
    De Cosmo, Salvatore
    Pellegrini, Fabio
    Ludovico, Ornella
    Frittitta, Lucia
    Trischitta, Vincenzo
    DIABETES, 2013, 62 : A430 - A430
  • [38] Efficacy and Safety of Sotagliflozin (SOTA) in Patients with Type 2 Diabetes (T2D) and Severe Renal Impairment
    Cherney, David
    Ferrannini, Ele
    Umpierrez, Guillermo E.
    Peters, Anne L.
    Rosenstock, Julio
    Carroll, Amy K.
    Lapuerta, Pablo
    Banks, Phillip L.
    Jiang, Wenjun
    Sawhney, Sangeeta
    DIABETES, 2020, 69
  • [39] Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes
    Williams-Herman, D.
    Johnson, J.
    Teng, R.
    Golm, G.
    Kaufman, K. D.
    Goldstein, B. J.
    Amatruda, J. M.
    DIABETES OBESITY & METABOLISM, 2010, 12 (05): : 442 - 451
  • [40] TREATMENT OF TYPE 2 DIABETES IN COLOMBIA: ECONOMIC EVALUATION OF SAXAGLIPTIN/METFORMIN EXTENDED-RELEASE (XR) FIXED-DOSE COMBINATION (FDC)
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Garrido Lecca, S.
    Aiello, E.
    Jimenez, C.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
12345